| 26.10 Data as of May 22 | +0.24 / +0.93%Today’s Change | 19.43 Today|||52-Week Range 31.36 | +14.67% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $1.7B |
Company Description
ViroPharma, Inc. is a biotechnology company. It develops and commercializes products that address serious diseases with a focus on products used by physician specialists in hospital settings. Its products include VANCOCIN and CINRYZE. The company focuses on providing products to physician specialists that support patients with serious diseases for which there is an unmet medical need, including disease caused by C1 esterase inhibitor deficiency and C. difficile. ViroPharma was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA.
Employees

Shareholders
| Mutual fund holders | 56.07% |
| Other institutional | 49.03% |
| Individual stakeholders | 24.26% |
Top Executives
| Vincent J. Milano, CPA | Chairman, President & Chief Executive Officer |
| Daniel B. Soland | Chief Operating Officer & Vice President |
| Charles A. Rowland, Jr., MBA | Chief Financial Officer & Vice President |
| Colin Broom, MD | Chief Scientific Officer & Vice President |
| Paul Firuta | Vice President & General Manager-Americas |